The p16 gene encoding a specific inhibitor of cyclin-dependent kinases 4 and 6 has been reported to be inactivated at a variety of rates in malignant tumors. We studied frequency and mechanism of inactivation of the p16 gene in various types of childhood acute lymphoblastic leukemia (ALL) using 36 
Introduction
Progression of the cell cycle in eukaryotic cells is strictly and skillfully regulated by the sequential formation, activation, and subsequent inactivation of a series of cyclin and cyclin-dependent kinase (CDK) complexes. [1] [2] [3] [4] The activation of CDK4 and CDK6 by cyclin D elicits phosphorylation of retinoblastoma protein (pRB), which result in release of several pRB-associated transcription factors required for G1 to S phase progression. 5, 6 Recently, frequent changes in status of cell cycle regulators, particularly overexpression of the cyclin D gene 7, 8 or inactivation of the RB gene, [9] [10] [11] have been demonstrated in a variety of neoplasms. However, in childhood acute lymphoblastic leukemia (ALL), alteration of the cyclin D or RB gene is not frequent. A family of proteins that bind and inhibit CDKs, which is generally referred to as inhibitors of CDKs (CDKI), have been isolated. Among these, p16/MTS1/INK4A has been shown to inhibit phosphorylation of pRB via its binding to the cyclin D-CDK4 or CDK6 complex, and its gene was assigned to the 9p21 locus, the most frequently deleted or rearranged site in childhood ALL. [12] [13] [14] [15] Thus, the p16 gene has been investigated as one of the important candidates for tumor suppressor gene in childhood ALL. The p15 gene, which is located in the vicinity of the p16 gene, has also been under investigation as another candidate. Previous studies have shown that homozygous deletion of the p16 gene is observed Correspondence: K Sugita, Department of Pediatrics, Yamanashi Medical University, 1110 Shimokato, Tamaho-cho, Nakakoma-gun, Yamanashi 409-3898, Japan; Fax: 81 (0) 55 273 6745 Received 23 July 1998; accepted 8 March 1999 in some childhood ALL, particularly T cell type, regardless of presence or absence of cytogenetic abnormalities at 9p21. 16, 17 In contrast, hypermethylation of the CpG island in the p16 gene, an alternative mechanism of gene inactivation, [18] [19] [20] [21] [22] [23] has not been shown in childhood ALL. 24 In the present study, to further clarify the significance of the p16 gene in childhood ALL, we examined the status of this gene in a large panel of leukemic cell lines established from patients with childhood ALL, and showed frequent inactivation of the p16 gene by methylation of the 5Ј CpG island in childhood ALL with 11q23 translocation. The same mechanism of inactivation of this gene was also found in some primary leukemia samples.
Materials and methods

Primary leukemia samples and cell lines
Thirty-six human leukemic cell lines established in our laboratory from patients with childhood ALL/Burkitt's lymphoma (BL) (B precursor, 28; B/BL, 3; and T, 5) were used as shown in Table 1 and their characteristics have been reported previously. 25-29 B precursor cell lines (n = 9) and primary leukemia samples (n = 8) with 11q23 translocation were extensively characterized in this study. An Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell line (BLCL) established from a normal donor was also used as a control.
Southern blot analysis
High-molecular weight DNA (5 g) isolated from each cell line was digested with BglII restriction enzyme (30 U), sizefractionated by electrophoresis on a 0.8% agarose gel, and transferred to nylon membranes (Hybond-N+; Amersham, Buckinghamshire, UK). Hybridization was performed with a ␣-32 P-dCTP-labeled 0.8-kb EcoRI/HincII p16 cDNA probe. 16 After two high stringent washes with 0.1 × SSC and 0.1% sodium dodecyl sulfate (SDS) at 65°C for 30 min, filters were exposed to X-ray film (XAR-5 film; Eastman-Kodak, Rochester, NY, USA) with an intensifying screen at −80°C. To confirm the amount and integrity of genomic DNA for each sample, blots were rehybridized with a probe prepared from human CD13 cDNA. 30 The ratio of the signal by the p16 probe to that by the CD13 probe was compared to define the presence of p16 deletion. When a different molecular weight band was visualized, the cell line was considered to have a rearrangement of the p16 gene in one allele.
In analysis of the methylated status of the p16 gene, 5 g of genomic DNA was double digested with methylation-sensitive enzyme, EagI or SacII (75 U) and -insensitive enzyme, EcoRI (50 U) for 16 h according to the manufacturer's instruction (New England Biolabs, Beverly, MA, USA). After fractionation 
BL, Burkitt's lymphoma; D/D, homozygous deletion; D/R, hemizygous deletion and a rearrangement in another allele; ±, partial methylation; ND, not determined; NT, not tested.
and transfer, hybridization was performed with a ␣-32 P-labeled probe including exon 1 of p16 generated by PCR method. The primers used were as follows; sense: 5Ј-GAA-GAAAGAGGAGGGGCTG-3Ј and antisense: 5Ј-GCGCTA-CCTGATTCCAATTC-3Ј. 31 After high stringent washes, filters were exposed to X-ray film.
Western blot analysis
1 × 10 6 leukemic cells in logarithmic phase of growth were solubilized in lysis buffer (50 mM Tris-HCl (pH 8.0), 0.15 M NaCl, 1% Nonidet P-40, 5 mM EDTA, 0.05% NaN 3 , 0.2 TIU/ml aprotinin, 1 g/ml pepstatin A, 10 mM iodoacetamide, 1 mM phenylmethylsulfonyl fluoride) on ice for 30 min. The lysates were separated on a 15% SDS-polyacrylamide gel under reducing conditions and then transferred to polyvinyl difluoride membranes (ATTO, Tokyo, Japan). After blocking with 5% nonfat dry milk in 0.05% Tween 20 Tris-buffered saline (TBST), membranes were incubated with murine antip16 monoclonal antibody (4 g/ml; Pharmingen, San Diego, CA, USA) in 5% milk-TBST at room temperature overnight. After washing with TBST, membranes were then incubated with horseradish peroxidase-coupled goat anti-mouse IgG (1:1000 dilution; Medical and Biological Laboratories, Nagoya, Japan) in 5% milk-TBST at room temperature for 1 h. After washing with TBST, membranes were developed using the enhanced chemiluminescence plus kit (Amersham). For confirmation of the integrity of cell lysates, membranes were reprobed with murine anti-human ␣-tubulin monoclonal antibody (1 g/ml, Sanbio, Uden, The Netherlands). In experiments for p16 induction by the demethylating agent, leukemic cells were cultured in the presence of 1 M 5-aza 2Ј deoxycytidine, harvested every day for 5 days, and the p16 expression was examined on Western blot.
Results
Southern blot analysis of the p16 gene
We first performed Southern blot analysis of the p16 gene using a panel of 36 leukemic cell lines. It is known that the p16 cDNA probe used not only hybridizes to genomic fragments including exons 1, 2, and 3 of p16 but also crosshybridizes weakly to the fragment including exon 2 of p15. As indicated in Figure 1a , the BglII fragments of 6.6-, 4.2-, and 5.0-kb include exons 1, 2, and 3 of the p16 gene, respectively. In addition, a 9.4-kb BglII fragment is shown to include exons 1 and 2 of the p15 gene. 16 The results were summarized in Table 1 , and are depicted in Figure 1b . Four bands detected in lanes 1 and 8 of BLCL were used as a positive control of intact p16 and p15 genes. Among B precursor-ALL cell lines, homozygous deletions and a hemizygous deletion with rearrangement in another allele of the p16 gene were detected in five (71%) and one (14%) of seven Ph1-positive cell lines, respectively. None of nine cell lines with 11q23 translocation showed homozygous or hemizygous deletion of the p16 gene. Two of four cell lines with t(1;19) showed homozygous deletions. Regarding two cell lines with 9p21 abnormalities, KOPN-46 retained biallelic p16 genes, whereas KOPN-39 had hemizygous deletion with rearrangement in another allele. KOPN-47 with del(9)(p21) did not reveal any bands, indicating homozygous deletions of the p16 and p15 genes. Only one of five cell lines with other chromosomal abnormalities showed homozygous deletion of p16. Homozygous deletions were not observed in all of the three B-ALL/BL cell lines, but very frequently (3/5; 60%) in T-ALL cell lines. As a whole, homozygous or hemizygous p16 deletions were observed in 14 of 36 (39%) childhood ALL/BL cell lines.
Western blot analysis of p16 protein
Next, we analyzed the p16 protein expression on Western blot in 24 cell lines not having homozygous deletion of this gene. Surprisingly, 20 cell lines (83%) did not reveal the p16 protein expression as shown in Figure 2 , indicating that the p16 gene is inactivated in these cell lines by mechanism(s) other than deletion. It should be noted that nine cell lines with 11q23 translocation as well as three B-ALL/BL cell lines showed no p16 protein expression despite their intact genes. Thus, the p16 protein expression was lost in 32 of 36 (89%) childhood leukemic cell lines.
Induction of the p16 protein expression after treatment with the demethylating agent
Recently, hypermethylation of the CpG island in the promoter region has been reported to be responsible for the p16 gene inactivation in a variety of malignant tumors. To assess a possible participation of hypermethylation in the p16 gene inactivation in childhood ALL/BL, we first investigated the time course of the p16 expression after treatment with the demethylating agent, 5-aza 2Ј deoxycytidine, using two representative cell lines. As shown in Figure 3 , in KOPB-26, p16 protein became detectable 2 days after treatment and reached maximal levels at day 4, while no induction was seen in KOPN66bi with homozygous deletion. Next, we tested nine cell lines with 11q23 translocation for p16 induction at day 4 after treatment. Eight of nine cell lines, except for KOCL-50, induced the p16 expression, but its amount varied depending on cell lines and their culture conditions (Figure 4a and b) . Of note, the induction was also observed in KOCL-50 in another experiment, indicating that the p16 gene is inactivated by hypermethylation in all of the cell lines with 11q23 translocation. As summarized in Table 1 , similar induction was also observed in four of five B precursor-ALL and three of three B-ALL/BL cell lines. 
Figure 3
Time course of the p16 protein induction after treatment with the demethylating agent. KOPB-26 with 11q23 translocation (lanes 1-6) and KOPN-66bi with Ph1 (lanes 7-12) were incubated with 5-aza 2Ј deoxycytidine for the indicated days, and the p16 protein induction was studied in each of the samples. The upper and lower panels show immunoblots by anti-p16 and anti-␣-tubulin monoclonal antibodies, respectively. The status of the p16 gene is shown as + (no deletion) or − (homozygous deletion).
Hypermethylation of the CpG island in the p16 gene
To more directly verify hypermethylation of the p16 gene in 18 cell lines which retain biallelic genes but lose protein expression, we performed Southern blot analysis using methylation-sensitive restriction enzymes. In addition to BLCL (no methylation control) and KOPT-11 (gene deletion control), four cell lines (KOPN-83bi, KOPN-63, KOPN-32 , KOPT-5), which express p16 before induction, were also examined as controls for no methylation as shown in Table 1 . As indicated in Figure 5a As shown in Figure 5b , BLCL revealed three bands with expected size by double digestion with EagI and EcoRI, whereas seven of nine cell lines with 11q23 translocation revealed a 4.3-kb fragment alone, indicating that the EagI site in the CpG island is methylated in these cell lines. KOCL-58 revealed both 4.3-and 3.3-kb bands, indicating partial methylation of the EagI site. Only one cell line KOCL-44 was not methylated at the EagI site. As shown in Figure 6a , the SacII sites were also not methylated in this cell line. However,
Figure 5
Southern blot analysis of the p16 gene using methylationsensitive and -insensitive restriction enzymes. p16 was strongly induced after 4 days' treatment with the demethylating agent (Figure 6b ), suggesting existence of methylation in the CpG island other than the EagI and SacII sites. In this regard, the induction experiment using the demethylating agent might be of simple and reliable methodology as a detection system of methylation-mediated gene inactivation. Similar hypermethylation of the CpG island was detected in seven (four B precursor-ALL and three B-ALL/BL) of nine cell lines which retain biallelic p16 genes but lose protein expression, whereas no methylation was revealed in one B-precursor ALL (KOPN-46) and one T-ALL (KOPT-K1) cell lines (Table 1) , suggesting mechanism(s) of gene inacti- vation other than deletion or hypermethylation. Thus, hypermethylation of the CpG island is a major mechanism of the p16 gene inactivation in childhood ALL/BL cell lines, particularly with 11q23 translocation.
Analysis of the p16 gene in primary samples with 11q23 translocation
To examine methylation status of the p16 gene in primary leukemia samples with 11q23 translocation, we performed Southern blot analysis using methylation-sensitive EagI and -insensitive EcoRI. As shown in Figure 7 , both 4.3-and 3.3-kb bands were found in three of eight cases (patients 1, 7 and 8), indicating that the EagI site in the CpG island is partially methylated. No methylation was detected at the EagI site in other five cases.
Discussion
Childhood ALL include phenotypically and genetically heterogeneous subtypes and show a wide variety of chromosomal abnormalities including translocations and deletions. 32 Among these, 11q23 translocation as well as Ph1 predict extremely poor prognosis even with the most intensified chemotherapy. 33, 34 In 11q23-related translocations, the MLL gene is rearranged and fused into a wide variety of genes localized on other chromosomes, resulting in production of several chimeric proteins such as MLL-AF4, MLL-AF9, and MLL-ENL. 35 The recent observation that chimeric mice carrying the MLL-AF9 fusion gene made by homologous recombination 36 developed leukemia indicated a direct contribution of these fusion genes to the leukemogenesis.
In the present study, we analyzed the status of the p16 gene in childhood ALL/BL cell lines, and demonstrated that the p16 gene was abrogated by deletion in six of seven (86%) Ph1-positive cell lines, in four of 12 (33%) B precursor-cell lines without Ph1 and 11q23 translocation, and in three of five (60%) T-ALL cell lines. This deletion rate was almost consistent with that shown in previous reports on leukemic cell lines 37 and clinical samples from childhood ALL; 15-25% in B precursor-ALL 16, 17 and 77-82% in T-ALL, 16, 17 although there was a marked discrepancy in deletion rate between cell lines (86%) and clinical samples (25%) with Ph1. 16, 37 The most striking observation in this study was that p16 protein was not detected in nine cell lines with 11q23 translocation, as well as three B-ALL/BL cell lines although they all had no deletion of p16. Regarding B-ALL/BL cell lines, it has been reported that 17 of 19 (90%) cell lines and eight of 19 (42%) or six of eight (75%) patients' samples showed hypermethylation of the p16 gene without deletion. 21, 38 We demonstrated re-activation of the p16 gene in all of the cell lines with 11q23 translocation after treatment with the demethylating agent, and directly verified hypermethylation of the CpG island in this gene on Southern blot using methylation-sensitive restriction enzymes. In analysis of patients' samples, we showed partial methylation of the p16 gene in three of eight cases. According to the reports by Iravani et al, 24 none of 29 children's samples with B precursor-ALL had hypermethylation of the p16 gene. Thus, the mechanism used for the p16 gene inactivation in ALL with 11q23 translocation is very unique among B precursor-ALL. Considering that MLL fusion proteins retain the methyltransferase (MT)-homologous domain of MLL in all types of translocations reported, 35 MLL fusion proteins might modify the methylation status of DNA including the p16 gene. High frequency of the p16 gene inactivation by hypermethylation have also been reported in patients' samples from other hematopoietic malignancies such as high grade non-Hodgkin's lymphoma (83%) 21 and multiple myeloma (75%). 18 In conclusion, our data indicated that the p16 gene inactivation was a common feature in childhood leukemic cell lines, but mechanism of inactivation was distinct depending on types of lineages (T or B) and chromosomal abnormalities (Ph1 or 11q23 translocation). The p16 gene inactivation by hypermethylation might play a role in the leukemogenesis and disease progression of ALL with 11q23 translocation.
